Japan · Delayed Price · Currency is JPY PeptiDream Earnings Call Transcripts
Fiscal Year 2025
-
2025 saw nearly double the clinical programs and strong radiopharmaceutical growth, though revenue missed forecasts due to delayed out-licensing. FY2026 guidance is conservative, with 6–12 new clinical programs expected and increased R&D investment, aiming for long-term revenue growth and pipeline expansion.
-
Significant R&D progress was made across radiopharmaceuticals and peptide therapeutics, with multiple programs advancing to clinical stages and robust growth in the radiopharmaceutical business. Major capital investments are underway to expand R&D and manufacturing capacity, supporting a strong outlook for continued pipeline expansion and innovation.
Fiscal Year 2024
-
Record FY2024 results with revenue up 163% and net income up nearly 500% year-over-year, driven by expanded partnerships and pipeline progress. FY2025 guidance is conservative, with upside potential from major out-licensing deals and continued pipeline expansion.
-
The company is rapidly expanding its radiopharmaceutical and peptide therapeutic pipelines, launching new internal programs and advancing multiple partnered assets into clinical stages. Platform innovations in automation and AI are accelerating discovery and optimization, supporting a goal of at least one new internal program annually.
-
First half FY2024 revenue and profit targets were exceeded, driven by the expanded Novartis collaboration and strong cash inflows. The company is well-positioned for further growth, with additional deals and milestones expected in H2 2024 and a robust pipeline across both radiopharmaceutical and non-radiopharmaceutical segments.